Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai’s Lecanemab Bags Fast-Track Status in US
December 27, 2021
- Kissei Files Rovatirelin for Spinocerebellar Degeneration in Japan
December 24, 2021
- Zogenix Files Dravet Syndrome Drug in Japan
December 23, 2021
- Takeda’s Eosinophilic Esophagitis Drug Rejected in US
December 23, 2021
- Kyowa Kirin, InveniAI Expand Collaboration in AI-Driven Drug Discovery
December 23, 2021
- Meiji to Launch Japan PIb/II of Hiyasta for B-cell Non-Hodgkin’s Lymphoma
December 23, 2021
- Ono Extends Drug Discovery Collaboration with Vanderbilt University in CNS
December 23, 2021
- Linepharma Submits NDA for Abortion Pills in Japan
December 23, 2021
- ITP Drug Fostamatinib Yields Positive Data in Japan PIII, Submission Eyed in 1st Half of 2022: Kissei
December 22, 2021
- Toray and 3SBio File NDA for Antipruritic Drug in China
December 22, 2021
- Actemra Production Has Doubled Since Start of COVID-19 Pandemic: Chugai CEO
December 22, 2021
- Healios, Hiroshima Univ. to Collaborate on Cancer Immunotherapy Using Gene-Edited NK Cells
December 22, 2021
- Daiichi Espha Rolls Out Authorized Generics for Artist, Sunrythm
December 21, 2021
- RaQualia Grants Global License for Chronic Pain Drug to Hisamitsu
December 21, 2021
- Takeda’s Vedolizumab Grabs EU Panel Nod for Chronic Pouchitis
December 21, 2021
- Astellas’ Padcev Gets Key European Backing for Bladder Cancer
December 21, 2021
- Shionogi’s Oral COVID-19 Drug Shows High Activity against Omicron
December 21, 2021
- Alnylam Seeks Japan Approval for Vutrisiran for FAP
December 21, 2021
- Mitsubishi Tanabe, 4 Partners Develop AI-Based Protein Crystal Structure Evaluation Technology
December 21, 2021
- Japan’s Dementia/MCI Market to Exceed 400 Billion Yen in 2030: Fuji Keizai
December 21, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…